Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies, has completed the acquisition of zPREDICTA. According to the announcement, the acquisition provides an immediate new anticipated revenue stream for POAI as well as supporting the company focus on developing new cancer therapies from drug discovery through regulatory approval. zPREDICTA is pioneering tumor-specific in vitro 3D cell culture models for drug discovery and development, and the acquisition is expected to be accretive both short and long term. “The acquisition of zPREDICTA adds an established company with clear synergies to Predictive Oncology’s team, not to mention a progressive revenue stream,” said Predictive Oncology CEO and chair J. Melville (“Mel”) Engle in the press release. “But it’s not just about what zPREDICTA is doing today or the revenue it’s generating now — it’s about how zPREDICTA will complement our larger efforts to accurately predict cancer treatment outcomes and optimal drug formulations to treat specific types of cancer in specific types of patients. zPREDICTA’s work in the development of new 3D cell culture methods gives us yet another competitive advantage in helping identify, develop, and expedite new cancer therapies.”
To view the full press release, visit https://ibn.fm/tUeEM
About Predictive Oncology Inc.
Predictive Oncology is a knowledge-driven company focused on applying artificial intelligence (“AI”) to develop personalized cancer therapies that can lead to more effective treatments and improved patient outcomes. As the drug-discovery community has now realized, a genomics-based approach to cancer research and drug development is insufficient to achieve the promise of personalized therapeutics. Predictive Oncology instead takes a multiomic approach, which accounts for the vast multitude of factors that make each cancer unique. Rather than operating based on the equivalent of a bird’s-eye view, Predictive Oncology makes possible a more personalized and effective approach to cancer research and treatment. For more information about the company, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.